AC Immune Ltd (ACIU)vsAlnylam Pharmaceuticals Inc (ALNY)
ACIU
AC Immune Ltd
$2.86
-0.69%
HEALTHCARE · Cap: $286.71M
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 103845% more annual revenue ($3.71B vs $3.57M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ACIU
Avoid14
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACIU.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACIU
The strongest argument for ACIU centers on Debt/Equity.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ACIU
The primary concerns for ACIU are EPS Growth, Market Cap, Profit Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ACIU profiles as a value stock while ALNY is a hypergrowth play — different risk/reward profiles.
ACIU carries more volatility with a beta of 1.65 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 14/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AC Immune Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?